STOCKHOLM, Oct. 25, 2024 /PRNewswire/ --

VALIANT Phase 3 results after presentation at ASN

Investors, analysts, and members of the media are invited to a conference call on Tuesday, October 29th, at 12:00 CET, 11:00 GMT, and 07:00 EDT. The call will include a presentation of results and insights from management and Professor Fadi Fakhouri following the American Society of Nephrology (ASN) and a Q&A session.

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.

To participate in the conference call, please use the following dial-in details:

Sweden: +46 8 5051 0031
United Kingdom: +44 207 107 06 13
United States: +1 631 570 56 13
For other countries, please find the details here.

Sobi

Sobi^® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

Gerard Tobin
Head of Investor Relations

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/invitation--sobi-s-aspaveli--and-the-phase-3-valiant-data-in-nephrology-call,c4056757

The following files are available for download:


     
     https://mb.cision.com/Main/14266/4056757/3075845.pdf Invitation Sobi's Aspaveli(R) and the Phase 3 VALIANT data in
                                                              Nephrology call

View original content:https://www.prnewswire.co.uk/news-releases/invitation-sobis-aspaveli-and-the-phase-3-valiant-data-in-nephrology-call-302287199.html

Tags

More Like This

Invitation: Sobi's Q3 2024 report

Invitation: Sobi's Q3 2023 report

Reminder: Invitation: Sobi's Q3 2023 report

Invitation: Sobi's Q1 2024 report

Invitation: Sobi's Q4 and FY 2023 report

Invitation: Sobi's Q2 2024 report

Reminder: Sobi KOL investor event: Advancing the standard of care in haemophilia

Sobi Q3 2024 report: Strong growth and significant pipeline momentum